Potential impact of nirsevimab and bivalent maternal vaccine against RSV bronchiolitis in infants: A population-based modelling study

Background: A new monoclonal antibody (nirsevimab; Beyfortus®) and a bivalent prefusion RSV vaccine (Abrysvo®) for maternal immunization have been approved recently. This is a modelling study to estimate the potential impact of different immunization programs with these products on RSV-bronchiolitis...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Principais autores: Mónica López-Lacort (Autor), Ana Corberán-Vallet (Autor), Francisco J. Santonja (Autor), Cintia Muñoz-Quiles (Autor), Javier Díez-Domingo (Autor), Alejandro Orrico-Sánchez (Autor)
Formato: Livro
Publicado em: Elsevier, 2024-08-01T00:00:00Z.
Assuntos:
Acesso em linha:Connect to this object online.
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Internet

Connect to this object online.

3rd Floor Main Library

Detalhes do Exemplar 3rd Floor Main Library
Número de Chamada: A1234.567
Cópia 1 Disponível